Answers are grounded in this paper and cite their sources.
Ranibizumab represents a novel therapy that, for the first time, appears to have the potential to enable many AMD patients to obtain a meaningful and sustained gain of vision. On June 30 2006, ranibizumab was approved by the US Food and Drug Administration for the treatment of wet AMD.
No takes yet. Share an insight, caveat, or question.
Ferrara et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: